CCM
SER icon

Chilton Capital Management’s Serina Therapeutics SER Stock Holding History

Chilton Capital Management’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 627
2021
Q4 		$0 Buy
+1
New +$27 ﹤0.01% 664

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Chilton Capital Management's SER Position: Q1 2022 in Review

Chilton Capital Management sold out of Serina Therapeutics (SER) in Q1 2022, closing a stake of 1 share.

Chilton Capital Management first reported a position in SER in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 32 funds tracked by Wall St. Rank hold SER as of Q1 2022.

  • Chilton Capital Management reported no remaining Serina Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Chilton Capital Management sold 1 Serina Therapeutics share in Q1 2022.
  • Chilton Capital Management first reported a position in Serina Therapeutics in Q4 2021 and held it in 1 quarter.
  • Chilton Capital Management's Serina Therapeutics position peaked at $0 in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Serina Therapeutics as of Q1 2022.

Based on Chilton Capital Management's 13F filing for Q1 2022, filed 16 May 2022.